Skip to main content

Flagship Pioneering — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

70
Companies
$4.6B
Total invested
$65.8M
Avg. check
23
Industries
Biotechnology 19Health Care 11Therapeutics 9Medical 9Life Science 6Pharmaceutical 4+17 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 25–48 of 70
Axcella
October 2022

Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.

Biotechnology · Cambridge$34.2M Post-IPO Equity
Cellarity
October 2022

Cellarity is a therapeutics company that uses genomic technologies, data science, and AI to develop a new generation of therapies.

Biotechnology · Somerville$121.0M Series C
Codiak Biosciences
September 2022

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics.

Biotechnology · San Francisco$20.0M Post-IPO Equity
Senda Biosciences
August 2022

Senda Biosciences is a therapeutics platform company leveraging unprecedented insights into the molecular connections between humans.

Biotechnology · Cambridge$123.0M Series C
ProFound Therapeutics
May 2022

ProFound Therapeutics is creating profound impacts on the understanding of biology and disease and the ability to create therapeutics.

Biotechnology · Cambridge$75.0M Series A
Vesalius Therapeutics
March 2022

Vesalius Therapeutics is focused on redefining the understanding and treatment of the diseases that drive ninety percent of human illness.

Biotechnology · Cambridge$75.0M Series A
Invaio Sciences
October 2021

Invaio Sciences is a technology company that is dedicated to solving pressing agriculture, nutrition, and environmental challenges.

Agriculture · Cambridge$50.0M Debt Financing
Tarveda Therapeutics
September 2021

Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors.

Biotechnology · Watertown$6.0M Venture - Series Unknown
Laronde
August 2021

Laronde develops an eRNA-based therapeutic platform that is capable of indicating diverse proteins inside the body.

Biotechnology · Cambridge$440.0M Series B
Foghorn Therapeutics
January 2026

Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express,

Biopharma · Cambridge$50.0M Post Ipo Equity
Denali Therapeutics
December 2025

Denali Therapeutics is dedicated to defeating neurodegenerative diseases to deliver safe and effective medicines to patients and families.

Biotechnology · San Francisco$200.0M Post Ipo Debt
Seres Therapeutics
October 2025

Seres Therapeutics is a microbiome therapeutics company that develops treatments for serious diseases.

Biopharma · Cambridge$3.6M Grant
Expedition Medicines
October 2025

Expedition Medicines is developing AI to stretch the bounds of medicine.

Advanced Materials · Cambridge$50.0M Series A
Extuitive
September 2025

Extuitive is an AI-first business that aims to revolutionize the conception and validation of new consumer goods and creatives.

Artificial Intelligence (AI) · Cambridge$20.0M Seed
Terrana Biosciences
July 2025

Terrana's innovative technology platform uses RNA-based plant health solutions to enable resilient agriculture for a world.

Agriculture · Cambridge$50.0M Series B
Etiome
April 2025

Etiome, a company redefining how we detect and preempt disease progression.

Biotechnology · Cambridge$50.0M Series A
Ampersand Biomedicines
March 2025

Ampersand Biomedicines is a multi-product platform that develops programmable medicines that target disease sites precisely.

Biopharma · Boston$65.0M Series B
Indigo
March 2025

Indigo is an agricultural technology company that focuses on improving sustainability and profitability in farming practices.

Agriculture · Boston$1.5M Series Unknown
Mirai Bio
September 2024

Mirai Bio provides access to end-to-end development capabilities with innovation at every step.

Artificial Intelligence (AI) · Cambridge$50.0M Series A
Apriori Bio
July 2024

Apriori Bio offers a platform for creating variant-resilient vaccines and provides real-time insights to prepare for future outbreaks.

Biotechnology · Boston$1.1M Grant
Prologue Medicines
May 2024

Prologue Medicines creates transformative medicines by systematically discovering and evaluating viral proteins and their unique features.

Health Care · Cambridge$50.0M Series A
CIBO
January 2024

CIBO scales regenerative advanced platform technology that connects growers to incentives and enterprises to growers.

Agriculture · Saint Louis ParkSeries C
Quotient Therapeutics
November 2023

Quotient Therapeutics engages in transformative medicines made possible with somatic genomics.

Biotechnology · London$50.0M Seed
Harbinger Health
September 2023

Harbinger Health is a biotechnology company that develops a two-tier testing model for the detection of early cancer with a blood test.

Artificial Intelligence (AI) · Cambridge$140.0M Series B

Where Flagship Pioneering invests

Biotechnology19
Health Care11
Therapeutics9
Medical9
Life Science6
Pharmaceutical4

About Flagship Pioneering's portfolio

How many companies has Flagship Pioneering invested in?▸

Flagship Pioneering has invested in 70 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Flagship Pioneering invest in?▸

Flagship Pioneering's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Life Science. The firm invests across 23 different industry categories.

What is Flagship Pioneering's largest investment?▸

Among tracked funding rounds, Laronde received $440.0M in a Series B round. Flagship Pioneering's total known invested capital is $4.6B.

What is the average investment size for Flagship Pioneering?▸

Flagship Pioneering's average investment size is $65.8M across its portfolio of 70 companies.

What are Flagship Pioneering's most recent investments?▸

Recent Flagship Pioneering portfolio additions include Axcella, Cellarity, Codiak Biosciences, Senda Biosciences, ProFound Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 70 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →